Evenity (romosozumab-aqqg) / UCB, Astellas, Amgen 
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
NCT05180032: Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Recruiting
4
39
US
Romoszumab, Evenity, Denosumab, Prolia, Placebo
James J. Peters Veterans Affairs Medical Center, Kessler Institute for Rehabilitation
Osteoporosis, Spinal Cord Injuries
03/25
03/27
NCT05101018: Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

Active, not recruiting
4
40
US
Romosozumab, Evenity, Denosumab, Prolia
James J. Peters Veterans Affairs Medical Center, Kessler Institute for Rehabilitation
Osteoporosis, Spinal Cord Injuries
11/25
11/27
NCT06079476: A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Recruiting
4
100
RoW
Romosozumab
Amgen
Postmenopausal Osteoporosis
11/25
11/25
NCT05067335: A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Completed
3
564
RoW
Romosozumab, Placebo
UCB Biopharma SRL
Osteoporosis
11/23
11/23
NCT04779216: Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

Active, not recruiting
3
30
US
Romosozumab Prefilled Syringe, Placebo, Alendronate 70Mg Tab
Karen Klahr Miller, MD, Amgen
Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
09/24
09/25
NCT05972551: Study to Evaluate Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Recruiting
3
106
Europe, Canada, Japan, US, RoW
Romosozumab, EVENITY®, Bisphosphonate
Amgen
Osteogenesis Imperfecta
02/27
05/27
NCT04232657: Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Active, not recruiting
2
36
US
Romosozumab, Evenity, Denosumab, Prolia, Placebo, Normal Saline (NS) injection
VA Office of Research and Development, Kessler Institute for Rehabilitation
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
02/26
03/27
NCT04708886: Romosozumab in Women With Chronic SCI

Completed
2
12
US
Romosozumab, Evenity, Alendronate, Fosamax
Northwestern University, Amgen
Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis
06/24
06/24
NCT04800367: Romosozumab/Denosumab Study for Premenopausal IOP

Recruiting
2
30
US
Romosozumab Prefilled Syringe [Evenity], Evenity, Denosumab 60 MG/ML Prefilled Syringe [Prolia], Prolia
Columbia University, Amgen
Premenopausal Idiopathic Osteoporosis
03/25
03/26
NCT04545554 / 2017-004972-74: Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

Completed
1
25
Europe, US, RoW
Romosozumab, Calcium, Vitamin D
Amgen
Osteogenesis Imperfecta
03/23
03/23

Download Options